Table 5.
National Cancer Institute Developmental Therapeutics Program In Vitro Testing Results of 13a.
| Cancer Types | Cell Line | GI50 (nM) | LC50 (nM) |
|---|---|---|---|
| Leukemia | CCRF-CEM | 40.6 | >10,000 |
| HL-60 | 34.2 | >10,000 | |
| K-562 | 35.2 | >10,000 | |
| MOLT-4 | 47.7 | >10,000 | |
| RPMI-8226 | 26.8 | >10,000 | |
| SR | 94.7 | >10,000 | |
| Non-Small Cell Lung Cancer | A549/ATCC | 176 | >10,000 |
| EKVX | 285 | >10,000 | |
| HOP-62 | 102 | >10,000 | |
| HOP-92 | 23.0 | >10,000 | |
| NCI-H226 | 52.3 | 460 | |
| NCI-H23 | 182 | >10,000 | |
| NCI-H322M | 173 | >10,000 | |
| NCI-H460 | 163 | >10,000 | |
| NCI-H522 | 96.9 | >10,000 | |
| Colon Cancer | COLO 205 | 29.8 | 660 |
| HCC-2998 | 143 | 1760 | |
| HCT-116 | 22.9 | 879 | |
| HCT-15 | 313 | >10,000 | |
| HT29 | 32.4 | >10,000 | |
| KM12 | 116 | >10,000 | |
| SW-620 | 53.0 | >10,000 | |
| CNS Cancer | SF-268 | 198 | >10,000 |
| SF-295 | 131 | >10,000 | |
| SF-539 | 98.9 | >10,000 | |
| SNB-19 | 231 | >10,000 | |
| SNB-75 | 312 | >10,000 | |
| U251 | 80.1 | 4280 | |
| Melanoma | LOX IMVI | 118 | 537 |
| MALME-3M | 48.2 | >10,000 | |
| M14 | 72.5 | >10,000 | |
| MDA-MB-435 | 97.5 | >10,000 | |
| SK-MEL-2 | 73.9 | >10,000 | |
| SK-MEL-28 | 68.7 | 893 | |
| SK-MEL-5 | 192 | >10,000 | |
| UACC-257 | 79.6 | >10,000 | |
| UACC-62 | 72.6 | 589 | |
| Ovarian Cancer | IGROV1 | 115 | >10,000 |
| OVCAR-3 | 135 | >10,000 | |
| OVCAR-4 | 105 | >10,000 | |
| OVCAR-5 | 31.6 | >10,000 | |
| OVCAR-8 | 41.3 | >10,000 | |
| NCI/ADR-RES | 516 | >10,000 | |
| SK-OV-3 | 98.3 | >10,000 | |
| Renal Cancer | 786–0 | 161 | >10,000 |
| ACHN | 85.5 | >10,000 | |
| CAKI-1 | 101 | 4300 | |
| RXF 393 | 23.4 | 666 | |
| SN12C | 158 | >10,000 | |
| TK-10 | 17.3 | >10,000 | |
| UO-31 | 173 | >10,000 | |
| Prostate Cancer | PC-3 | 54.2 | >10,000 |
| DU-145 | 90.8 | >10,000 | |
| Breast Cancer | MCF7 | 106 | >10,000 |
| MDA-MB-231/ATCC | 203 | >10,000 | |
| HS 578T | 121 | >10,000 | |
| BT-549 | 338 | >10,000 | |
| T-47D | 23.9 | >10,000 | |
| MDA-MB-468 | 50.4 | >10,000 |